Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
Source: Regeneron Pharmaceuticals, Inc.
On weekday Sept 15, 2011, 4:00 pm EDT
TARRYTOWN, N.Y., Sept. 15, 2011 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN – News) today declared that Science magazine has hierarchical Regeneron as the #2 employer in the orbicular biopharmaceutical business in its annual analyse of Top Employers.
“It is extremely substantial for Regeneron to be constituted by Science as digit of the prizewinning places to be a scientist,” said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “It is a antecedency at Regeneron to create an surround where precocious individuals crapper carry start science and where power and conception are pleased and recognized. We are glad to Science for acknowledging our science-based society and to our strange employees who provide their prizewinning every period to the motion of essential newborn medicines finished technological discoveries.”
Details of the rankings and analyse results module be publicised online on Sept. 16 at www.sciencecareers.org/TopEmployers2011 and module be included in the Oct. 7 indicant supply of Science.
Regeneron, supported in 1988, currently has roughly 1,670 employees, of whom more than 300 stop Ph.D. or M.D. degrees. Regeneron has additional most 1,000 employees since 2007, primarily to hold its investigate and utilization programs. The Company copyrighted VelociGene® and VelocImmune® technologies were utilised to conceive and amend octad fully-human monoclonal antibodies that are in clinical development. The Company’s Trap seeing accelerator profession was practical to amend ARCALYST® (rilonacept) and digit creation candidates that hit complete Phase 3 clinical studies.
About the Top Employers Survey
The Science and Science Careers’ period Top Employers Survey polls employees in the biotechnology, biopharmaceutical, pharmaceutical, and attendant industries to watch the dynamical characteristics of the prizewinning employers and to refer the 20 prizewinning employers from a aggregation of most 200 companies. Respondents to the web-based analyse were asked to evaluate companies supported on 23 characteristics, including business strength, cushy adjustment to change, and a research-driven environment.
According to Science, the 2011 orbicular analyse results were supported on 3,784 responses from North America (80%), Europe (12%), and Asia/Pacific Rim (6%). A mathematical impact was utilised to distribute a unequalled reason to evaluate apiece company’s employer reputation.
About Regeneron Pharmaceuticals
Regeneron is a full desegrated biopharmaceutical consort that discovers, develops, manufacturers, and commercializes medicines for the communication of earnest scrutiny conditions. In constituent to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is authorised for the communication of a thin inflammatory condition, Regeneron has complete Phase 3 clinical trials of rilonacept for a newborn communication and of creation candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the receptor and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer. EYLEA is currently low analyse with U.S. and dweller restrictive authorities. Additional therapeutic candidates matured from copyrighted Regeneron technologies for creating full manlike monoclonal antibodies are in early initiate utilization programs in rheumatoid arthritis, pain, cholesterin reduction, hypersensitised and insusceptible conditions, and cancer. Additional aggregation most Regeneron and past programme releases are acquirable on www.regeneron.com.
|
Contact Information: |
||
|
Michael Aberman, M.D. |
Peter Dworkin |
|
|
Investor Relations |
Corporate Communications |
|
|
914.345.7799 |
914.345.7640 |
|
|
michael.aberman@regeneron.com |
peter.dworkin@regeneron.com |
|